Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Brain Res ; 798(1-2): 320-4, 1998 Jul 06.
Artículo en Inglés | MEDLINE | ID: mdl-9666158

RESUMEN

The effects of intrathecal pretreatment with aminophylline on intrathecal norepinephrine-produced or serotonin-produced suppression of noxiously evoked discharges in thalamic parafascicular neurons were investigated in 35 urethane-anesthetized rats. The results showed that: (1) both intrathecal norepinephrine (15 nmol) or serotonin (20 nmol) produced significant suppression of noxiously evoked discharges in parafascicular neurons; (2) intrathecal aminophylline (120 nmol) blocked the norepinephrine-produced suppression of noxiously evoked discharges, while the same dose of aminophylline exhibited no significant effect on the serotonin-produced suppression of these discharges in parafascicular neurons. The results suggest that spinal norepinephrine-produced, but not serotonin-produced, antinociceptive effects may be mediated by adenosine as one of successive chemical links in the spinal dorsal horn circuitry.


Asunto(s)
Adenosina/farmacología , Neuronas/fisiología , Nociceptores/efectos de los fármacos , Norepinefrina/administración & dosificación , Tálamo/fisiología , Aminofilina/administración & dosificación , Aminofilina/farmacología , Animales , Electrofisiología , Femenino , Inyecciones Espinales , Masculino , Norepinefrina/farmacología , Ratas , Ratas Sprague-Dawley , Serotonina/administración & dosificación , Serotonina/farmacología , Tálamo/citología
2.
J Clin Oncol ; 6(6): 947-54, 1988 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-3286830

RESUMEN

The Southwest Oncology Group (SWOG) colorectal adjuvant study 7510 went through two phases. From 1975 to 1977, 309 patients were randomized to chemotherapy alone or the same chemotherapy plus immunotherapy. From 1977 until 1980, 317 patients were randomized among the same two therapy programs and a control group. With a minimum follow-up in either phase of greater than 7 years, data are now mature. They show no difference in relapse-free survival (RFS) nor overall survival (OS) in either the two-way phase or in the three-way phase. There is no indication, except possibly in one very small subset, that the addition of immunotherapy to chemotherapy provides an improvement in OS or in RFS. Using data from patients accrued after randomization to the control group, we fail to find evidence that either chemotherapy alone or chemoimmunotherapy improves OS or RFS when contrasted to outcomes obtained by patients on the control arm. In fact, we have significant evidence, at the P = .016 level, that chemotherapy does not improve OS by at least 50%; we also have significant evidence, at the P = .011 level, that chemoimmunotherapy will not improve OS by at least 25%. No evidence of efficacy was demonstrated for either treatment regimen, even though enough therapy was given to result in significant toxicities. Acute toxicity was at least moderate, but not fatal, in 75% of patients. Recognizable delayed toxicity included rare cases of fatal renal failure and acute leukemia.


Asunto(s)
Adenocarcinoma/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias del Colon/terapia , Neoplasias del Recto/terapia , Adenocarcinoma/mortalidad , Adolescente , Adulto , Anciano , Vacuna BCG/administración & dosificación , Ensayos Clínicos como Asunto , Neoplasias del Colon/mortalidad , Terapia Combinada , Femenino , Fluorouracilo/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Neoplasias del Recto/mortalidad , Semustina/administración & dosificación
3.
Lasers Surg Med ; 3(3): 199-209, 1983.
Artículo en Inglés | MEDLINE | ID: mdl-6668975

RESUMEN

Kodak projectors with #2418 red Corning filters were used as a light source to treat cutaneous and subcutaneous malignancies in five patients who previously had been given hematoporphyrin derivative (HpD). An argon dye laser system was used to treat malignancies in patients who also were given the HpD. These tumors included 11 melanomas of the eye, three carcinomas of the esophagus, one melanoma of the esophagus, four carcinomas of the lung, three basal cell skin cancers, and one retropharyngeal metastatic oral cancer. Clinical results and technical problems of this therapy are discussed.


Asunto(s)
Terapia por Láser , Fotoquimioterapia , Fototerapia/métodos , Neoplasias Cutáneas/terapia , Adenocarcinoma/terapia , Anciano , Neoplasias de la Mama/terapia , Neoplasias de los Bronquios/terapia , Carcinoma Basocelular/terapia , Carcinoma de Células Escamosas/secundario , Carcinoma de Células Escamosas/terapia , Terapia Combinada , Equipos y Suministros , Neoplasias Esofágicas/terapia , Femenino , Neoplasias de Cabeza y Cuello/secundario , Neoplasias de Cabeza y Cuello/terapia , Humanos , Neoplasias Pulmonares/terapia , Masculino , Melanoma/terapia , Persona de Mediana Edad , Recurrencia Local de Neoplasia/terapia , Neoplasias Cutáneas/secundario
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA